{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:18:14Z","timestamp":1770895094267,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare, Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japanese Agency for Medical Research and development, AMED","award":["15fk0210001h0002"],"award-info":[{"award-number":["15fk0210001h0002"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.antiviral.2016.07.003","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T18:40:31Z","timestamp":1467744031000},"page":"262-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment"],"prefix":"10.1016","volume":"132","author":[{"given":"Yasunori","family":"Nio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikari","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7488-9362","authenticated-orcid":false,"given":"Hitomi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Miyayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Akahori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hijikata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.07.003_bib1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.gastro.2013.05.014","article-title":"Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers","volume":"145","author":"Abe","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2016.07.003_bib2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1128\/AAC.02053-12","article-title":"Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme Oxygenase-1 induction","volume":"57","author":"Chen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.07.003_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2016.07.003_bib4","unstructured":"ClinicalTrialsgov Identifier: NCT00790556, last updated: February 11, 2016, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00790556?term=NCT+00790556&rank=1."},{"issue":"6","key":"10.1016\/j.antiviral.2016.07.003_bib5","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1194\/jlr.M700050-JLR200","article-title":"Involvement of ACSL in local synthesis of neutral lipids in cytoplasmic lipid droplets in human hepatocyte HuH-7","volume":"48","author":"Fujimoto","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.antiviral.2016.07.003_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2016.07.003_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.bbrc.2006.03.059","article-title":"Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporine A, and NIM811","volume":"343","author":"Goto","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.antiviral.2016.07.003_bib8","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.0409834102","article-title":"Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids","volume":"102","author":"Kapadia","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.07.003_bib10","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1038\/srep04549","article-title":"Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes","volume":"4","author":"Lyn","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2016.07.003_bib11","doi-asserted-by":"crossref","first-page":"50301","DOI":"10.1074\/jbc.M305684200","article-title":"Hepatitis C virus non-structural protein in the probable membranous compartment function in viral genome replication","volume":"278","author":"Miyanari","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.07.003_bib12","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/ncb1631","article-title":"The lipid droplet is an important organelle for hepatitis C virus production","volume":"9","author":"Miyanari","year":"2007","journal-title":"Nat. Cell Biol."},{"issue":"21","key":"10.1016\/j.antiviral.2016.07.003_bib14","doi-asserted-by":"crossref","first-page":"12311","DOI":"10.1128\/JVI.01678-14","article-title":"Searoyl coenzyme A desaturase 1 is associated with hepatitis C virus replication complex and regulates viral replication","volume":"88","author":"Nyguyen","year":"2014","journal-title":"J.\u00a0Virol."},{"issue":"14","key":"10.1016\/j.antiviral.2016.07.003_bib15","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1021\/jm200319u","article-title":"Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia","volume":"54","author":"Oballa","year":"2011","journal-title":"J.\u00a0Med. Chem. 28"},{"key":"10.1016\/j.antiviral.2016.07.003_bib16","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/JCM.00838-12","article-title":"Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy","volume":"50","author":"Svarovskaia","year":"2012","journal-title":"J.\u00a0Clin. Microbiol."},{"issue":"6","key":"10.1016\/j.antiviral.2016.07.003_bib17","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.27202","article-title":"Telaprevir-based treatment effects on hepatitis C virus in liver and blood","volume":"60","author":"Talal","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2016.07.003_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1146\/annurev.bi.52.070183.002541","article-title":"Fatty acid synthesis and its regulation","volume":"52","author":"Wakil","year":"1983","journal-title":"Ann. Rev. Biochem."},{"issue":"9","key":"10.1016\/j.antiviral.2016.07.003_bib19","first-page":"5155","article-title":"Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity antimicrobial agents and chemotherapy","volume":"58","author":"Wang","year":"2014"},{"key":"10.1016\/j.antiviral.2016.07.003_bib20","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/hep.22508","article-title":"Fatty acid synthase is upregulated during HCV Infection and regulates HCV entry and production","volume":"48","author":"Yang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2016.07.003_bib21","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1038\/cddis.2013.60","article-title":"Targeting cellular metabolism to improve cancer therapeutics","volume":"4","author":"Zhao","year":"2013","journal-title":"Cell Death Dis."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421630198X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421630198X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T14:24:25Z","timestamp":1536589465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421630198X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":19,"alternative-id":["S016635421630198X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.07.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}